Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Abarelix: Difference between pages
Appearance
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 456664060 of page Abarelix for the Chem/Drugbox validation project (updated: 'DrugBank', 'CAS_number'). |
→References: Fixed spacing between stub template and category templates. |
||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Abarelix|oldid=456664060}} 456664060] of page [[Abarelix]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = |
||
| IUPAC_name = acetyl- |
| IUPAC_name = acetyl----D-4--D-3----L-N-methyl-tyrosyl-D-asparagyl-L-leucyl--isopropyl-lysyl-L-prolyl-D--<!--not validated by [[Wikipedia:WikiProject Pharmacology]]--> |
||
| image = Abarelix.svg |
| image = Abarelix.svg |
||
| width = 250px |
|||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
| Drugs.com = {{drugs.com|monograph|abarelix}} |
| Drugs.com = {{drugs.com|monograph|abarelix}} |
||
| |
| = |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| class = [[GnRH analogue]]; [[GnRH antagonist]]; [[Antigonadotropin]] |
|||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = 96–99% |
| protein_bound = 96–99% |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
|||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CASNo_Ref = {{cascite|??|??}} |
|||
| CAS_number_Ref = {{cascite|changed|??}} |
| CAS_number_Ref = {{cascite|changed|??}} |
||
| CAS_number = |
| CAS_number = 183552-38-7 |
||
| CAS_supplemental = |
| CAS_supplemental = |
||
| ATC_prefix = L02 |
| ATC_prefix = L02 |
||
| ATC_suffix = BX01 |
| ATC_suffix = BX01 |
||
| ATC_supplemental = |
| ATC_supplemental = |
||
| PubChem = 16131215 |
| PubChem = 16131215 |
||
| IUPHAR_ligand = 1188 |
| IUPHAR_ligand = 1188 |
||
| DrugBank_Ref = {{drugbankcite| |
| DrugBank_Ref = {{drugbankcite||drugbank}} |
||
| DrugBank = DB00106 |
| DrugBank = DB00106 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
Line 41: | Line 43: | ||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
| ChEMBL = 1252 |
| ChEMBL = 1252 |
||
| synonyms = |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=72 | H=95 | Cl=1 | N=14 | O=14 |
| C=72 | H=95 | Cl=1 | N=14 | O=14 |
||
⚫ | |||
| molecular_weight = 1416.06 g/mol |
|||
⚫ | |||
| InChI = 1/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1 |
|||
| InChIKey = AIWRTTMUVOZGPW-HSPKUQOVBF |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1 |
| StdInChI = 1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1 |
||
Line 53: | Line 53: | ||
| StdInChIKey = AIWRTTMUVOZGPW-HSPKUQOVSA-N |
| StdInChIKey = AIWRTTMUVOZGPW-HSPKUQOVSA-N |
||
}} |
}} |
||
'''Abarelix''', sold under the brand name '''Plenaxis''', is an injectable [[gonadotropin-releasing hormone]] antagonist ([[gonadotropin-releasing hormone antagonist|GnRH antagonist]]) which is marketed in [[Germany]] and the [[Netherlands]]. It is primarily used in [[oncology]] to reduce the amount of [[testosterone]] made in patients with advanced symptomatic [[prostate cancer]] for which no other treatment options are available.<ref name="Drugs.com-2">{{cite web | work = Drugs.com | url = https://www.drugs.com/mtm/abarelix.html | title = Abarelix | access-date = 2018-01-23 | archive-date = 2018-02-10 | archive-url = https://web.archive.org/web/20180210163254/https://www.drugs.com/mtm/abarelix.html | url-status = dead }}</ref><ref>{{cite journal | vauthors = Boccon-Gibod L, van der Meulen E, Persson BE | title = An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer | journal = Therapeutic Advances in Urology | volume = 3 | issue = 3 | pages = 127–40 | date = June 2011 | pmid = 21904569 | pmc = 3159401 | doi = 10.1177/1756287211414457 }}</ref> |
|||
It was originally marketed by Praecis Pharmaceuticals as ''Plenaxis'',<ref name="Drugs.com-2" /> and is now marketed by Speciality European Pharma in Germany<ref>Pharmazeutische Zeitung online: [http://www.pharmazeutische-zeitung.de/index.php?id=4760 Abarelix] {{in lang|de}}</ref> after receiving a marketing authorization in 2005. The drug was introduced in the [[United States]] in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe [[allergic reaction]]s.<ref name="Minev2011">{{cite book| first = Boris | last = Minev | name-list-style = vanc |title=Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures|url=https://books.google.com/books?id=mOdKDLAAd0AC&pg=PA182|date=13 January 2011|publisher=Springer Science & Business Media|isbn=978-90-481-9704-0|pages=182–}}</ref> It remains marketed in [[Germany]] and the [[Netherlands]] however.<ref name="Drugs.com">{{cite web | title = Abarelix | url = https://www.drugs.com/international/abarelix.html | work = Drugs.com | access-date = 2018-08-27 | archive-date = 2019-08-29 | archive-url = https://web.archive.org/web/20190829113846/https://www.drugs.com/international/abarelix.html | url-status = dead }}</ref> |
|||
== See also == |
|||
* [[Gonadotropin-releasing hormone receptor#Antagonists|Gonadotropin-releasing hormone receptor § Antagonists]] |
|||
== References == |
|||
{{Reflist}} |
|||
{{GnRH and gonadotropins}} |
|||
{{GnRH and gonadotropin receptor modulators}} |
|||
[[Category:GnRH antagonists]] |
|||
[[Category:Peptide therapeutics]] |
|||
{{pharma-stub}} |